Metastatic VIPoma presenting as an ovarian mass
CONCLUSION In conclusion, this case proves that although uncommon, PNET can show metastases in both ovaries even a decade after initial diagnosis. (Source: International Journal of Surgery Case Reports)
Source: International Journal of Surgery Case Reports - November 24, 2015 Category: Surgery Source Type: research
A short history of neuroendocrine tumours and their peptide hormones
Publication date: Available online 23 October 2015 Source:Best Practice & Research Clinical Endocrinology & Metabolism Author(s): Wouter W. de Herder, Jens F. Rehfeld, Mark Kidd, Irvin M. Modlin The discovery of neuroendocrine tumours of the gastrointestinal tract and pancreas started in 1870, when Rudolf Heidenhain discovered the neuroendocrine cells, which can lead to the development of these tumours. Siegfried Oberndorfer was the first to introduce the term carcinoid in 1907. The pancreatic islet cells were first described in 1869 by Paul Langerhans. In 1924, Seale Harris was the first to des...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - October 23, 2015 Category: Endocrinology Source Type: research
A 25-Year Experience of Gastroenteropancreatic Neuroendocrine Tumors and Somatostatin (Congeners) Analogs: From Symptom Control to Antineoplastic Therapy.
Authors: O'Dorisio TM, Anthony LB
Abstract
Radioimmunoassay technology was utilized in the discovery of somatostatin and was quickly brought into therapeutics; however, it took the development of somatostatin congeners to solve its limitations of a short half-life. Therapeutic medical control of hyperhormonal states such as acromegaly, carcinoid syndrome and VIPoma significantly advanced from a nonspecific approach to one that specifically and effectively targeted the underlying pathophysiology. Clinical care was transformed from nonspecific symptom control to one of a significant improvement in not only q...
Source: Frontiers of Hormone Research - August 27, 2015 Category: Endocrinology Tags: Front Horm Res Source Type: research
Pancreatic VIPoma visualized by 68Ga DOTA-NOC PET-CT.
PMID: 26235641 [PubMed - in process] (Source: Nuklearmedizin)
Source: Nuklearmedizin - August 3, 2015 Category: Radiology Authors: Wimmer I, Minear G, Brustbauer R, Götzinger P, Dam K Tags: Nuklearmedizin Source Type: research
Intractable and Dramatic Diarrhea in Liver Transplantation Recipient With Vasoactive Intestinal Peptide-producing Tumor After Split Liver Transplantation: A Case Report
Diarrhea after liver transplantation is a common complication. Vasoactive intestinal peptide-producing tumor (VIPoma) is a rare cause of watery diarrhea; 80% of such tumors occur in the pancreas, but it is rare in liver. Hypersecretion of vasoactive intestinal polypeptide can stimulate intestinal water and electrolyte secretion, and patients with VIPoma present with watery diarrhea, hypokalemia, and dehydration. Here we report on a 50-year-old man who presented with a 7-month history of watery diarrhea. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - January 14, 2015 Category: Transplant Surgery Authors: W. Haiqing, Y. Jiayin, Y. Jian, Y. Lunan Source Type: research
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male
Publication date: September 2014 Source:Hematology/Oncology and Stem Cell Therapy, Volume 7, Issue 3 Author(s): Ahmed Abu-Zaid , Ayman Azzam , Zainab Abudan , Amani Algouhi , Hadeel Almana , Tarek Amin VIPoma is an exceedingly unusual neuroendocrine neoplasm that autonomously secretes vasoactive intestinal polypeptide (VIP). Its reported incidence is approximately 1 per 10 million individuals per year. Herein, we report the case of sporadic pancreatic VIPoma in a 47-year-old male who presented with a six-month history of chronic, plentiful, watery diarrhea. On physical examination, the patient looked sick, lethar...
Source: Hematology Oncology and Stem Cell Therapy - October 12, 2014 Category: Cancer & Oncology Source Type: research
Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis
CONCLUSIONSThe results of this retrospective study suggest a possible survival benefit for the use of octreotide LAR in elderly patients with distant‐stage NET with carcinoid syndrome. The results of the current study also suggest that octreotide LAR is underused in this population despite recommended guidelines. Cancer 2014. © 2014 American Cancer Society. (Source: Cancer)
Source: Cancer - March 26, 2014 Category: Cancer & Oncology Authors: Chan Shen, Ya‐Chen Tina Shih, Ying Xu, James C. Yao Tags: Original Article Source Type: research
[Case Report] VIPoma in a 37-year-old man
In September, 2011, a 37-year-old man with a past history of pulmonary tuberculosis came to our hospital with persistent watery diarrhoea, weight loss, and hypokalaemia of 2 years' duration. The diarrhoea did not stop with fasting, and serum potassium had remained at 2·5 mmol/L despite multiple cycles of intravenous potassium replacement. Physical examination and routine blood investigations were normal, as were both upper and lower gastrointestinal tract endoscopies. An abdominal CT showed a 5·9 × 3·4 cm lesion in the pancreatic tail and a solitary hepatic metastasis, confirmed by MRI (). (Source: LANCET)
Source: LANCET - August 30, 2013 Category: Journals (General) Authors: Stanley Lam, Huiling Liew, Hong Tar Khor, Rinkoo Dalan, Yin Chian Kon, Michelle Jong, Daniel EK Chew, Melvin Khee-Shing Leow Tags: Case Report Source Type: research
